SCN CARRIES OUT MSEK 37 RIGHTS ISSUE WITH MSEK 10 GREENSHOE OPTION TO SECURE DUE TO EXPECTED INCREASED DEMAND FOR THE COMPANY’S PRODUCTS

(NGM:SCN)

The Board of Scandinavian Clinical Nutrition i Sverige AB (publ), suggests that an Extraordinary General Meeting decides to issue shares and convertible bonds with preferential right for the company’s shareholders with a greenshoe option. The purpose of the rights issue is to secure an expected increase in need for working capital due to increased demand for SCN’s products, for example due to the OTC registration of troxerutin (Coldizin). 80 percent of the rights issue is already secured through subscription engagements and underwriting guarantees from members of the board, major shareholders and other investors.

• The gross proceeds for SCN, excluding the greenshoe option, will be about MSEK 37 if the rights issue is fully subscribed for.

• Right to subscribe for new shares and convertible bonds shall with preferential right be due for the shareholders of SCN, and for each one (1) held share, the shareholder will be given one (1) unit right. Each twelve (12) unit rights entitle to the subscription of one (1) Unit.

• One (1) Unit consists of one (1) share at a subscription price of SEK 10 and one (1) convertible bond at par value of SEK 20. One (1) convertible bond gives the holder the right to convert it to one (1) new share in SCN at a price of SEK 20.

• The subscription price is SEK 30 per Unit.

• As a result of the rights issue, at full conversion of the convertible bonds, the share capital in SCN will increase by 246,512 SEK through the issue of 2,465,120 shares (with a par value of SEK 0.10).

• 80 percent of the rights issue is secured through subscription engagement and underwriting guarantees from the members of the board, major shareholders and other investors

• A greenshoe issue of SEK 10 is issued to Glitnir Corporate Finance with the aim to widening the shareholding base, thus increase the liquidity in the share.

Estimated time schedule

• Extraordinary General Meeting: May 12, 2008

• Record date: May 19, 2008

• Trading in unit rights: May 28, 2008 – June 9, 2008

• Subscription period: May 28, 2008 – June 12, 2008

Glitnir Corporate Finance AB is financial advisor to SCN in conjunction with the right issue.

For more information, please contact:

Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81

Thomas Christensen, CFO, tc@scnutrition.com, +47 922 55 444

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).